Please type a plus sign (+) inside this box [+]

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known	
Application Number	09/101,518
Filing Date	December 21, 1998
First Named Inventor	Li
Group Art Unit	1646
Examiner Name	Pak, M.
Attorney Docket Number	PF218US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MDP	AA	5,155,218	B1	Weinshank et al.	10-13-1992	
	AB	5,374,506	B1	Murphy	12-20-1994	
	AC	5,786,157	B1	Weinshank et al.	07-28-1998	
	AD	5,882,855	B1	Weinshank et al.	03-16-1999	
	AE	5,935,925	B1	Weinshank et al.	08-10-1999	
	AF	6,140,064	B1	Loetscher et al.	10-31-2000	
	AG	6,171,590	B1	Howard et al.	01-09-2001	
MDP	AH	6,184,358	B1	Loetscher et al.	02-06-2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
MDP	AI	WO	91/17174	A1	Neurogenetic Corporation	11-14-1991		
	AJ	WO	92/00986	A1	Neurogenetic Corporation	01-23-1992		
	AK	WO	92/18641	A1	Trustees of Boston University; Repligen Corporation	10-29-1992		
	AL	WO	93/06229	A1	United States of America	04-01-1993		
	AM	WO	98/11218	A1	Theodor-Kocher Institute; Leukosite	03-19-1998		
	AN	WO	98/32858	A2	Schering Corporation	07-30-1998		
	AO	WO	99/50299	A1	Astra Pharmaceuticals Ltd.	10-07-1999		
	AP	WO	00/18431	A1	Corixa Corporation	04-06-2000		
MDP	AQ	WO	00/22129	A1	Arena Pharmaceuticals	04-20-2000		

Examiner Signature	MICHAEL PAK	Date Considered	12/12/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box [+]

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known	
Application Number	09/101,518
Filing Date	December 21, 1998
First Named Inventor	Li
Group Art Unit	1646
Examiner Name	Pak, M.
Attorney Docket Number	PF218US

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
MDP	AR	SAMBROOK et al., Molecular Cloning. New York: Cold Spring Harbor Laboratory Press. 1989, 2nd ed., pages 10.2-10.3 and 10.29-10.35.	
	AS	MARCHESE et al., "Cloning of human genes encoding novel G protein-coupled receptors," Genomics 23(3):609-18, October 1994.	
	AT	MILLS et al., "Orphan seven transmembrane domain receptors: reversing pharmacology," Trends in Biotechnol. 12:47-49, 1994.	
	AU	HEIBER et al., "Isolation of three novel human genes encoding G protein-coupled receptors," DNA Cell Biol. 14(1):25-35, January 1995.	
	AV	LOETSCHER et al., GenBank Accession No. P49682, "C-X-C chemokine receptor type 3 (CXC-R3) (CXCR-3) (CKR-L2)," June 1, 1996.	
	AW	MARCHESE et al., GenBank Accession No. U32674, "Human orphan receptor GPR9 (GPR9) gene, partial cds," June 5, 1996.	
	AX	LOETSCHER et al. "Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes," J. Exp. Med. 184(3):963-969, 1996.	
	AY	LOETSCHER et al., GenBank Accession No. X95876, "H.sapiens mRNA for G-protein coupled receptor," May 16, 1997.	
	AZ	LOETSCHER et al., GenBank Accession No. CAA65126, "G-protein coupled receptor [Homo sapiens]," May 16, 1997.	
	BA	GUTIERREZ et al., GenBank Accession No. Z79783, "H.sapiens G protein-coupled receptor CKR-L2," July 26, 1997.	
	BB	GUTIERREZ et al., GenBank Accession No. CAB02143, "G PROTEIN-COUPLED RECEPTOR CKR-L2 [Homo sapiens]," July 26, 1997.	
	BC	SOTO et al., "The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3," Proc. Natl. Acad. Sci. USA 95:8205-8210, July 1998.	
	BD	Geneseq Accession No. AAV26557, "Human IP-10/Mig receptor CXCR3 gene," August 14, 1998.	
	BE	Geneseq Accession No. AAW54371, "Human IP-10/Mig receptor CXCR3 protein," August 14, 1998.	
	BF	TAMARU et al., "Cloning of the murine interferon-inducible protein 20 (IP-10) receptor and its specific expression in lymphoid organs," Biochem. Biophys. Res. Commun. 251(1):41-48, October 9, 1998.	
	BG	TAMARU et al., GenBank Accession No. BAA34045, "interferon-inducible protein 10 receptor [mus musculus]," October 28, 1998.	
MDP	BH	Geneseq Accession No. AAW69999, "Rodent chemokine receptor HST01.1 amino acid sequence," October 30, 1998.	

Examiner Signature	MICHAEL PAK	Date Considered	12/12/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box [+]

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known	
Application Number	09/101,518
Filing Date	December 21, 1998
First Named Inventor	Li
Group Art Unit	1646
Examiner Name	Pak, M.
Attorney Docket Number	PF218US

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
MPP	BI	BALASHOV et al., "CCR5$^+$ and CXCR3$^+$ T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions," Proc. Natl. Acad. Sci. USA 96:6873-6878, June 1999.	
	BJ	TRENTIN et al., "The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis," J. Clin. Invest. 104(1):115-121, July 1999.	
	BK	LU et al., "Structure and function of the murine chemokine receptor CXCR3," Eur. J. Immunol. 29(11):3804-12, November 1999.	
	BL	KOGA et al., "T cell infiltration into class II MHC-disparate allografts and acute rejection is dependent on the IFN-γ-induced chemokine Mig," J. Immunol. 163:4878-4885, 1999.	
	BM	Geneseq Accession No. AAZ32713, "Human chemokine receptor CXCR3b cDNA," January 31, 2000.	
	BN	Geneseq Accession No. AAY50129, "Human chemokine receptor CXCR3b," January 31, 2000.	
	BO	WANG et al., GenBank Accession No. AAF76982, "chemokine receptor CXCR3 [Rattus norvegicus]," June 19, 2000.	
	BP	TAMARU et al., GenBank Accession No. JE0349, "interferon-inducible protein 10 (IP-10) receptor – mouse," July 21, 2000.	
	BQ	JONES et al., "Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma," Blood 96(2):685-690, July 15, 2000.	
	BR	Geneseq Accession No. AAY79372, "Human chemokine receptor CXCR3," August 1, 2000.	
	BS	Geneseq Accession No. AAA30593, "Human G protein-coupled receptor GPR9 cDNA," August 21, 2000.	
	BT	Geneseq Accession No. AAY90614, "Human G protein-coupled receptor GPR9," August 21, 2000.	
	BU	Geneseq Accession No. AAA30714, "DNA encoding human mutant G protein-coupled receptor GPR9 (M254K)," August 21, 2000.	
	BV	Geneseq Accession No. AAY90648, "Human mutant G protein-coupled receptor GPR9 (M254K)," August 21, 2000.	
	BW	SOTO et al., GenBank Accession No. O88410, "C-X-C chemokine receptor type 3 (CXC-R3) (CXCR-3)," October 9, 2000.	
	BX	GenBank Accession No. NM_001504, "Homo sapiens G protein-coupled receptor 9 (GPR9)," October 31, 2000.	
MPP	BY	GenBank Accession No. NP_001495, "G protein-coupled receptor 9; chemokine (C-X-C) receptor 3 [Homo sapiens]," October 31, 2000.	

Examiner Signature	MICHAEL PAK	Date Considered	12/12/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box [+]

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known	
Application Number	09/101,518
Filing Date	December 21, 1998
First Named Inventor	Li
Group Art Unit	1646
Examiner Name	Pak, M.
Attorney Docket Number	PF218US

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
MDP	BZ	GenBank Accession No. NP_034040, "chemokine (C-X-C) receptor 3 [mus musculus]," November 1, 2000.	
	CA	HANCOCK et al., "Requirement of the chemokine receptor CXCR3 for acute allograft rejection," J. Exp. Med. 192(10):1515-1519, November 20, 2000.	
	CB	ALBANESI et al., "IL-4 enhances keratinocyte expression of CXCR3 agonistic chemokines," J. Immunol. 165:1395-1402, 2000.	
	CC	ARIMILLI et al., "Chemokines in autoimmune diseases," Immuno. Rev. 177:43-51, 2000.	
	CD	CASCIERI et al., "The chemokine/chemokine-receptor family: potential and progress for therapeutic intervention," Curr. Op. Chem. Bio. 4:420-427, 2000.	
	CE	SIMPSON et al., "Expression of the interferon-γ-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions," Neuropath. & Applied Neurobiol. 26:133-142, 2000.	
	CF	WANG et al., "Identification and molecular characterization of rat CXCR3: receptor expression and interferon-inducible protein-10 binding are increased in focal stroke," Mol. Pharmacol. 57:1190-1198, 2000.	
	CG	PATEL et al., "CXCR3 and CCR5 ligands in rheumatoid arthritis synovium," Clin. Immunol. 98(1):39-45, January 2001.	
	CH	BONACCHI et al., "Signal transduction by the chemokine receptor CXCR3," J. Biol. Chem. 276(13):9945-9954, March 30, 2001.	
	CI	ROMAGNANI et al., "Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity," J. Clin. Invest. 107(1):53-63, 2001.	
MDP	CJ	SEBASTIANI et al., "Chemokine receptor expression and function in $CD4^+$ T lymphocytes with regulatory activity," J. Immunol. 166:996-1002, 2001.	

Examiner Signature	MICHAEL PAK	Date Considered	12/12/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.